Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Drilon

Showing results (161-170 of 268) with videos related to

Pageof 27
Sort By:
Cancer Research|January 16, 2019
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase FusionsEmiliano Cocco, Jamal Benhamida, Sumit Middha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP RegistryArianna Marinello, Julia K Rotow, Meghanne Lomibao, et al.
Nature Communications|March 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket studyMrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2023
Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 InactivationSoo-Ryum Yang, Erika Gedvilaite, Ryan Ptashkin, et al.
Annals of the American Thoracic Society|February 21, 2026
The Complementary Roles of EBUS-Guided Needle Aspiration, Mini-Forceps, and Cryobiopsy in the Investigation of Mediastinal LesionsOr Kalchiem-Dekel, Brie E Kezlarian-Sachs, Xiaoyue Ma, et al.
JCO Precision Oncology|November 16, 2023
Amplification of Wild-Type <i>RET</i> Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to SelpercatinibMalini M Gandhi, Biagio Ricciuti, Guilherme Harada, et al.
The New England Journal of Medicine|June 1, 2026
Selpercatinib in Early-Stage <i>RET</i> Fusion-Positive Non-Small-Cell Lung CancerYi-Long Wu, Maximilian Hochmair, Yi Yang, et al.
European Journal of Endocrinology|March 25, 2022
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinomaSteven G Waguespack, Alexander Drilon, Jessica J Lin, et al.
The Journal of Molecular Diagnostics : JMD|May 17, 2025
Leveraging RNA from DNA Extraction Lysate to Rescue "Insufficient" Samples for More Comprehensive Genomic Profiling in Patients with Scant Tumor SpecimensMark D Ewalt, Sara E DiNapoli, Kerry Mullaney, et al.
Nature Reviews. Clinical Oncology|October 1, 2024
Two decades of advances in clinical oncology - lessons learned and future directionsSusana Banerjee, Christopher M Booth, Eduardo Bruera, et al.
Pageof 27

Showing results (161-170 of 268) with videos related to

Sort By:
Pageof 27
Cancer Research|January 16, 2019
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase FusionsEmiliano Cocco, Jamal Benhamida, Sumit Middha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP RegistryArianna Marinello, Julia K Rotow, Meghanne Lomibao, et al.
Nature Communications|March 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket studyMrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2023
Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 InactivationSoo-Ryum Yang, Erika Gedvilaite, Ryan Ptashkin, et al.
Annals of the American Thoracic Society|February 21, 2026
The Complementary Roles of EBUS-Guided Needle Aspiration, Mini-Forceps, and Cryobiopsy in the Investigation of Mediastinal LesionsOr Kalchiem-Dekel, Brie E Kezlarian-Sachs, Xiaoyue Ma, et al.
JCO Precision Oncology|November 16, 2023
Amplification of Wild-Type <i>RET</i> Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to SelpercatinibMalini M Gandhi, Biagio Ricciuti, Guilherme Harada, et al.
The New England Journal of Medicine|June 1, 2026
Selpercatinib in Early-Stage <i>RET</i> Fusion-Positive Non-Small-Cell Lung CancerYi-Long Wu, Maximilian Hochmair, Yi Yang, et al.
European Journal of Endocrinology|March 25, 2022
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinomaSteven G Waguespack, Alexander Drilon, Jessica J Lin, et al.
The Journal of Molecular Diagnostics : JMD|May 17, 2025
Leveraging RNA from DNA Extraction Lysate to Rescue "Insufficient" Samples for More Comprehensive Genomic Profiling in Patients with Scant Tumor SpecimensMark D Ewalt, Sara E DiNapoli, Kerry Mullaney, et al.
Nature Reviews. Clinical Oncology|October 1, 2024
Two decades of advances in clinical oncology - lessons learned and future directionsSusana Banerjee, Christopher M Booth, Eduardo Bruera, et al.
Pageof 27